Skip to main content
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs,

Dr. John Cush RheumNow

3 years 10 months ago
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/mEkaa7Yjt1 https://t.co/BaMYHiG5Pb
RT @DrCassySims: Highlights from the @ACRheum Kawasaki Disease Guidelines
🥇IVIG is mainstay therapy (2 g/kg)
👶ðŸ

Catherine Sims, MD DrCassySims

3 years 10 months ago
Highlights from the @ACRheum Kawasaki Disease Guidelines 🥇IVIG is mainstay therapy (2 g/kg) 👶🏼 Use ASA in acute KD 🗣Refractory cases may require steroids or additional immunosuppression 🫀Get echos on all patients to assess for coronary aneurysms
Tawanese claims analysis of 10,857 RA pts shows lower CVA rates when taking Celebrex (5.95% vs 9.72% not taking) or Etor

Dr. John Cush RheumNow

3 years 10 months ago
Tawanese claims analysis of 10,857 RA pts shows lower CVA rates when taking Celebrex (5.95% vs 9.72% not taking) or Etoricoxib (2.69% vs 8.51% not taking). Both Celebrex/Etoricoxib significantly reduced stroke risk p < 0.001 https://t.co/6idrH9g0LJ https://t.co/d80bEtsP7k
FDA has approves RINVOQ (upadacitinib) for the treatment of Active Non-Radiographic Axial Spondyloarthritis https://t.

Dr. John Cush RheumNow

3 years 10 months ago
FDA has approves RINVOQ (upadacitinib) for the treatment of Active Non-Radiographic Axial Spondyloarthritis https://t.co/DMuQFjFdrf https://t.co/zLsniZ2zOg
Health Canada has approved EVUSHELD to treat COVID-19 in immunocompromised patients (it was previously approved to preve

Dr. John Cush RheumNow

3 years 10 months ago
Health Canada has approved EVUSHELD to treat COVID-19 in immunocompromised patients (it was previously approved to prevent COVID) https://t.co/ePgd4DjTka https://t.co/whgSM3ce7Q
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM

Dr. John Cush RheumNow

3 years 10 months ago
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM
ACR Award Winners (10.21.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.
“If you torture the data long enough it will confess”-Ronald Coase (economist) https://t.co/ZGivhUWLZW

Dr. John Cush RheumNow

3 years 10 months ago

“If you torture the data long enough it will confess” -Ronald Coase (economist) https://t.co/ZGivhUWLZW

How do Pts check Temps? Paired oral &amp; temporal temps in 2031 Blacks &amp; 2344 Whites: / whites showed no diff (36.9

Dr. John Cush RheumNow

3 years 10 months ago

How do Pts check Temps? Paired oral & temporal temps in 2031 Blacks & 2344 Whites: / whites showed no diff (36.97 vs 36.95°C), but signif diff in blacks (36.98 vs 37.05). Fever seen in 10.2-10.8% Whites, but 10.1% (temporal), 13.2% (oral) in Blacks https://t.co/D4XowfsYXD https://t.co/LmvEnAVGbr

Vaccination Cut Long COVID Risk for Rheum Patients
  • MedPage Today
Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.
Pregnancy Outcomes with Belimumab

A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pr

Dr. John Cush RheumNow

3 years 11 months ago
Pregnancy Outcomes with Belimumab A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects. https://t.co/cXm58iSmVc https://t.co/Hdg6Qg1uHE
Prevotella Immune Response in Both Pre-Clinical &amp; Established RA

In a recent analysis published in Arthritis &amp;

Dr. John Cush RheumNow

3 years 11 months ago
Prevotella Immune Response in Both Pre-Clinical & Established RA In a recent analysis published in Arthritis & Rheumatology, people at risk for RA and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). https://t.co/6zArTx4XlM https://t.co/9UIk2OOhXq
Difficult to treat RA (D2T-RA) study of 48 D2T-145 non-D2T-RA pts. D2T-RA was predicted by Not starting MTX w/in 3 mos (

Dr. John Cush RheumNow

3 years 11 months ago
Difficult to treat RA (D2T-RA) study of 48 D2T-145 non-D2T-RA pts. D2T-RA was predicted by Not starting MTX w/in 3 mos (17% vs 33% non-D2T-RA;p= 0.011) &being on steroids > 6 mos (71% vs 34%, p< 0.001). https://t.co/Ugbr7z7mia https://t.co/TCU7wSfMrS
mRNA COVID vaccine study from Vaccine Safety Datalink shows risk of myocarditis/pericarditis 0-7d post Vax (ages 5-39) i

Dr. John Cush RheumNow

3 years 11 months ago
mRNA COVID vaccine study from Vaccine Safety Datalink shows risk of myocarditis/pericarditis 0-7d post Vax (ages 5-39) is ~1/200K doses (1st dose), 1/ 30K(2nd dose), 1/50K (1st booster); w/ higher risk in adolescent males https://t.co/J1u038qxB7 https://t.co/vEUNbOvEQf
×